Beyond chemotherapy: targeted therapies in ovarian cancer

doi:10.1038/nrc2583

Review

. 2009 Mar;9(3):167-81.

doi: 10.1038/nrc2583.

Beyond chemotherapy: targeted therapies in ovarian cancer

Timothy A Yap¹, Craig P Carden, Stan B Kaye

Affiliations

PMID: 19238149
DOI: 10.1038/nrc2583

Free article

Review

Beyond chemotherapy: targeted therapies in ovarian cancer

Timothy A Yap et al. Nat Rev Cancer. 2009 Mar.

Free article

. 2009 Mar;9(3):167-81.

doi: 10.1038/nrc2583.

Authors

Timothy A Yap¹, Craig P Carden, Stan B Kaye

Affiliation

¹ The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. stan.kaye@rmh.nhs.uk

PMID: 19238149
DOI: 10.1038/nrc2583

Abstract

Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine.

Trial registration: ClinicalTrials.gov NCT00429793 NCT00523432 NCT00610714 NCT00628251 NCT00753545.

PubMed Disclaimer

Cited by

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Ihnen M, et al. Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31. Mol Cancer Ther. 2013. PMID: 23729402 Free PMC article.
MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
Cebulla J, Huuse EM, Pettersen K, van der Veen A, Kim E, Andersen S, Prestvik WS, Bofin AM, Pathak AP, Bjørkøy G, Bathen TF, Moestue SA. Cebulla J, et al. Br J Cancer. 2015 Feb 3;112(3):504-13. doi: 10.1038/bjc.2014.628. Epub 2014 Dec 23. Br J Cancer. 2015. PMID: 25535727 Free PMC article.
Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.
Hervent AS, De Keulenaer GW. Hervent AS, et al. Int J Mol Sci. 2012 Sep 26;13(10):12268-86. doi: 10.3390/ijms131012268. Int J Mol Sci. 2012. PMID: 23202898 Free PMC article. Review.
Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells.
Nakamura K, Takae S, Shiraishi E, Shinya K, Igualada AJ, Suzuki N. Nakamura K, et al. Sci Rep. 2020 Oct 13;10(1):17058. doi: 10.1038/s41598-020-74087-9. Sci Rep. 2020. PMID: 33051529 Free PMC article.
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X, Chong Y, Liu H, Han Y, Niu M. Liu X, et al. J Ovarian Res. 2015 Jun 10;8:35. doi: 10.1186/s13048-015-0166-y. J Ovarian Res. 2015. PMID: 26055813 Free PMC article.

See all "Cited by" articles

References

1. Gynecol Oncol. 1991 Jul;42(1):3-8 - PubMed
1. Clin Cancer Res. 2005 Aug 1;11(15):5539-48 - PubMed
1. Cancer. 2002 Feb 1;94(3):707-12 - PubMed
1. Gynecol Oncol. 1993 Jul;50(1):78-83 - PubMed
1. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Gynecol Oncol. 1991 Jul;42(1):3-8 - PubMed

[2] Gynecol Oncol. 1991 Jul;42(1):3-8 - PubMed

[3] Clin Cancer Res. 2005 Aug 1;11(15):5539-48 - PubMed

[4] Clin Cancer Res. 2005 Aug 1;11(15):5539-48 - PubMed

[5] Cancer. 2002 Feb 1;94(3):707-12 - PubMed

[6] Cancer. 2002 Feb 1;94(3):707-12 - PubMed

[7] Gynecol Oncol. 1993 Jul;50(1):78-83 - PubMed

[8] Gynecol Oncol. 1993 Jul;50(1):78-83 - PubMed

[9] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 - PubMed

[10] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Beyond chemotherapy: targeted therapies in ovarian cancer

Affiliation

Beyond chemotherapy: targeted therapies in ovarian cancer

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous